Actinomycin D

CHF 75.00
In stock
BVT-0089-M0055 mgCHF 75.00
BVT-0089-M02525 mgCHF 225.00
BVT-0089-M100100 mgCHF 650.00
 
More Information
Product Details
Synonyms Actinomycin IV; Actinomycin C1; Dactinomycin
Product Type Chemical
Properties
Formula C62H86N12O16
MW 1255.4
Merck Index 14: 2800
CAS 50-76-0
RTECS AU1575000
Source/Host Chemicals Isolated from Streptomyces parvulus.
Purity Chemicals ≥98% (HPLC)
Appearance Red shiny crystals.
Solubility Soluble in DMSO, 100% ethanol or methanol.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Other Product Data Sensitive to strong acids and bases.
InChi Key ZOWMRHVAQGTFTG-IZRKADTCSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
After reconstitution protect from light at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antibiotic.
  • Antitumor compound [2].
  • Cytotoxic [2].
  • Apoptosis inducer [1, 2, 6, 7].
  • RNA synthesis inhibitor [4].
  • DNA intercalating agent [3, 5].
  • Mcl-1 expression inhibitor [8]
  • p53 pathway activator [9].
Product References
  1. Apoptosis induced by Actinomycin D, Camptothecin or Aphidicolin can occur in all phases of the cell cycle: J.M. Glynn, et al.; Biochem. Soc. Trans. 20, 84S (1992)
  2. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells: J. Kleeff, et al.; Int. J. Cancer 86, 399 (2000)
  3. Influence of DNA base sequence on the binding energetics of actinomycin D: S.A. Bailey, et al.; Biochemistry 32, 5881 (1993)
  4. Effect of actinomycin on RNA synthesis and antibody formation in the anamnestic response in vitro: J.D. Smiley, et al.; J. Exp. Med. 119, 881 (1964)
  5. NMR Solution Structure of a DNA-Actinomycin D Complex Containing a Non-Hydrogen-Bonding Pair in the Binding Site: S.L. Cravens, et al.; J. Am. Chem. Soc. 132, 17588 (2010)
  6. Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes: I. Kalousek, et al.; Anticancer Drugs 18, 763 (2007)
  7. Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells: M.J. Wang, et al.; Neurosci. Res. 59, 40 (2007)
  8. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression: K.E. Olberding, et al.; Cancer Biol. Ther. 10, 930 (2010)
  9. Specific activation of the p53 pathway by low dose actinomycin D: M. L. Choong, et al.; Cell Cycle 8, 2810 (2009)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.